GSK, Vir to collaborate on new therapeutics for influenza
17th Feb 2021 12:02
(Sharecast News) - GlaxoSmithKline and Vir Biotechnology will expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
Read moreSanofi Covid-19 vaccines may be ready by end of 2021
15th Feb 2021 12:17
(Sharecast News) - French drug giant Sanofi's two vaccine candidates against Covid-19 may be ready by year-end, the company said, refuting an earlier report.
Read moreThursday broker round-up
11th Feb 2021 14:18
(Sharecast News) - JD Wetherspoons: Peel Hunt downgrades to reduce with a target price of 1,150p.
Read moreFriday broker round-up
5th Feb 2021 13:27
(Sharecast News) - Burberry: Goldman Sachs upgrades to neutral with a target price of 1,690p.
Read moreDeutsche Bank cuts GlaxoSmithKline to 'sell', says valuation alone is not enough
4th Feb 2021 15:54
(Sharecast News) - Analysts at Deutsche Bank downgraded their recommendation for shares of GlaxoSmithKline to "sell" following the UK drug giant's latest quarterly update.
Read moreThursday broker round-up
4th Feb 2021 12:55
(Sharecast News) - GSK: Deutsche Bank downgrades to sell with a target price of 1,150p.
Read moreGlaxoSmithKline forecasts decline in 2021 earnings, shares slump
3rd Feb 2021 12:11
(Sharecast News) - Shares of GlaxoSmithKline slumped on Wednesday after the pharmaceuticals giant said it expects 2021 earnings to decline, as it reported growth in revenues and profit for 2020.
Read moreGSK, Curevac to develop vaccine for Covid-19 variants
3rd Feb 2021 07:01
(Sharecast News) - GlaxoSmithKline and CureVac on Wednesday announced a new venture to develop a vaccine targeting emerging variants of Covid-19 in one jab.
Read moreGlaxo not seeking re-hearing in Ellipta litigation, says Vectura
29th Dec 2020 10:04
(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.
Read moreGlaxoSmithKline's ViiV gets EU authorisation for complete HIV treatment
21st Dec 2020 08:08
(Sharecast News) - GlaxoSmithKline announced on Monday that its majority-owned HIV-specialist ViiV Healthcare had received marketing authorisation for the first complete, long-acting injectable HIV treatment in Europe.
Read moreSunday newspaper round-up: Tier 4 lockdown, Business rates, Debt binge
20th Dec 2020 19:41
(Sharecast News) - Boris Johnson yesterday revealed in a 4pm emergency press conference that a third of England - including London and swathes of the home counties - would be thrust into a brutal Tier 4 lockdown from midnight on Saturday in a bid to stamp out the 'mutant' strain of coronavirus. The draconian bracket forced all non-essential shops to shut giving Britons just eight hours to complete their gift shopping ahead of Christmas Day. - Financial Mail on Sunday
Read moreGSK and Sanofi delay Covid-19 vaccine
11th Dec 2020 07:02
(Sharecast News) - G|axoSmithKline and Sanofi have delayed their Covid-19 vaccine programme after their vaccine showed a weak response in people aged 50 and over.
Read moreCourt denies GSK appeal in Vectura intellectual property dispute
20th Nov 2020 08:34
(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.
Read moreGlaxoSmithKline upbeat on HIV treatment test results in women
9th Nov 2020 08:12
(Sharecast News) - GlaxoSmithKline announced on Monday that the independent data safety monitoring board of ViiV Healthcare had recommended the early unblinding of the HIV Prevention Trials Network (HPTN) '084' study, evaluating the safety and efficacy of investigational, long-acting, injectable 'cabotegravir' for HIV prevention in women.
Read moreGSK sees FY EPS at lower end of guidance as Covid hits vaccines business
28th Oct 2020 12:03
(Sharecast News) - GlaxoSmithKline said on Wednesday that it's on track to deliver full-year adjusted earnings per share at the lower end of its guidance range as the company's vaccines business has taken a hit from the Covid-19 pandemic.
Read more